Lion Biotechnologies to Participate in Upcoming Investor and Scientific Conferences

NEW YORK, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Lion Biotechnologies (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that president and CEO Elma Hawkins, PhD, will participate in the following upcoming investor and scientific conferences:

FBR Second Annual Healthcare Conference
Date: Wednesday, September 9, 2015
Location: The Four Seasons Hotel, Boston

CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival
Date: Wednesday – Saturday, September 16-19, 2015
Panel: Roundtable Discussion: The Regulatory Landscape for Cell and Gene Therapy, Thursday, September 17, 12:05p.m. - 1:35p.m
Location: Sheraton New York Times Square Hotel, New York

About Lion Biotechnologies

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) for the treatment of patients with refractory metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and Moffitt Cancer Center. For more information, please visit

Forward Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties described in the Company's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Relations The Trout Group Gitanjali Ogawa 646-378-2949

Source:Lion Biotechnologies, Inc.